|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar
|
|
2
|
Ragazzi M, Ciarrocchi A, Sancisi V,
Gandolfi G, Bisagni A and Piana S: Update on anaplastic thyroid
carcinoma: Morphological, molecular, and genetic features of the
most aggressive thyroid cancer. Int J Endocrinol. 2014:7908342014.
View Article : Google Scholar
|
|
3
|
Nagaiah G, Hossain A, Mooney CJ,
Parmentier J and Remick SC: Anaplastic thyroid cancer: A review of
epidemiology, pathogenesis and treatment. J Oncol. 2011:5423582011.
View Article : Google Scholar
|
|
4
|
Smallridge RC, Ain KB, Asa SL, Bible KC,
Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal
MS, et al: American thyroid association guidelines for management
of patients with anaplastic thyroid cancer. Thyroid. 22:1104–1139.
2012. View Article : Google Scholar
|
|
5
|
Molinaro E, Romei C, Biagini A, Sabini E,
Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini
A, Torregrossa L, et al: Anaplastic thyroid carcinoma: From
clinicopathology to genetics and advanced therapies. Nat Rev
Endocrinol. 13:644–660. 2017. View Article : Google Scholar
|
|
6
|
Kebebew E, Greenspan FS, Clark OH, Woeber
KA and McMillan A: Anaplastic thyroid carcinoma. Treatment outcome
and prognostic factors. Cancer. 103:1330–1335. 2005. View Article : Google Scholar
|
|
7
|
Are C and Shaha AR: Anaplastic thyroid
carcinoma: Biology, pathogenesis, prognostic factors, and treatment
approaches. Ann Surg Oncol. 13:453–464. 2006. View Article : Google Scholar
|
|
8
|
Sasanakietkul T, Murtha TD, Javid M, Korah
R and Carling T: Epigenetic modifications in poorly differentiated
and anaplastic thyroid cancer. Mol Cell Endocrinol. 469:23–37.
2018. View Article : Google Scholar
|
|
9
|
Saini S, Maker AV, Burman KD and Prabhakar
BS: Molecular aberrations and signaling cascades implicated in the
pathogenesis of anaplastic thyroid cancer. Biochim Biophys Acta Rev
Cancer. 1872:1882622019. View Article : Google Scholar
|
|
10
|
Robertson SC, Tynan J and Donoghue DJ: RTK
mutations and human syndromes: When good receptors turn bad. Trends
Genet. 16:3682000. View Article : Google Scholar
|
|
11
|
Adams GP and Weiner LM: Monoclonal
antibody therapy of cancer. Nat Biotechnol. 23:1147–1157. 2005.
View Article : Google Scholar
|
|
12
|
Geng L, Wang XT, Yu J and Yang YL:
Antagonism of cortistatin against cyclosporine-induced apoptosis in
rat myocardial cells and its effect on myocardial apoptosis gene
expression. Eur Rev Med Pharmacol Sci. 22:3207–3213. 2018.
|
|
13
|
Ronsin C, Muscatelli F, Mattei MG and
Breathnach R: A novel putative receptor protein tyrosine kinase of
the met family. Oncogene. 8:1195–1202. 1993.
|
|
14
|
Camp ER, Liu W, Fan F, Yang A, Somcio R
and Ellis LM: RON, a tyrosine kinase receptor involved in tumor
progression and metastasis. Ann Surg Oncol. 12:273–281. 2005.
View Article : Google Scholar
|
|
15
|
Wang MH, Lee W, Luo YL, Weis MT and Yao
HP: Altered expression of the RON receptor tyrosine kinase in
various epithelial cancers and its contribution to tumourigenic
phenotypes in thyroid cancer cells. J Pathol. 213:402–411. 2007.
View Article : Google Scholar
|
|
16
|
Hunt BG, Davis JC, Fox LH, Vicente-Muñoz
S, Lester C, Wells SI and Waltz SE: RON-augmented cholesterol
biosynthesis in breast cancer metastatic progression and
recurrence. Oncogene. 42:1716–1727. 2023. View Article : Google Scholar
|
|
17
|
Zheng XJ, Chen WL, Yi J, Li W, Liu JY, Fu
WQ, Ren LW, Li S, Ge BB, Yang YH, et al: Apolipoprotein C1 promotes
glioblastoma tumorigenesis by reducing KEAP1/NRF2 and CBS-regulated
ferroptosis. Acta Pharmacol Sin. 43:2977–2992. 2022. View Article : Google Scholar
|
|
18
|
Chen J, Wang K, Ye S, Meng X, Jia X, Huang
Y and Ma Q: Tyrosine kinase receptor RON activates MAPK/RSK/CREB
signal pathway to enhance CXCR4 expression and promote cell
migration and invasion in bladder cancer. Aging (Albany NY).
14:7093–7108. 2022. View Article : Google Scholar
|
|
19
|
Ma X, Xu J, Gao N, Tian J and Song T:
Dexmedetomidine attenuates myocardial ischemia-reperfusion injury
via inhibiting ferroptosis by the cAMP/PKA/CREB pathway. Mol Cell
Probes. 68:1018992023. View Article : Google Scholar
|
|
20
|
Sun RF, Zhao CY, Chen S, Yu W, Zhou MM and
Gao CR: Androgen receptor stimulates hexokinase 2 and induces
glycolysis by PKA/CREB signaling in hepatocellular carcinoma. Dig
Dis Sci. 66:802–813. 2021. View Article : Google Scholar
|
|
21
|
Farhat D, Ghayad SE, Icard P, Le Romancer
M, Hussein N and Lincet H: Lipoic acid-induced oxidative stress
abrogates IGF-1R maturation by inhibiting the CREB/furin axis in
breast cancer cell lines. Oncogene. 39:3604–3610. 2020. View Article : Google Scholar
|
|
22
|
Xu Y, Han YF, Ye B, Zhang YL, Dong JD, Zhu
SJ and Chen J: miR-27b-3p is involved in doxorubicin resistance of
human anaplastic thyroid cancer cells via targeting peroxisome
proliferator-activated receptor gamma. Basic Clin Pharmacol
Toxicol. 123:670–677. 2018. View Article : Google Scholar
|
|
23
|
Sakamuru S, Zhao J, Attene-Ramos MS and
Xia M: Mitochondrial membrane potential assay. Methods Mol Biol.
2474:11–19. 2022. View Article : Google Scholar
|
|
24
|
Park JS, Choi HI, Kim DH, Kim CS, Bae EH,
Ma SK and Kim SW: RON receptor tyrosine kinase regulates epithelial
mesenchymal transition and the expression of pro-fibrotic markers
via Src/Smad signaling in HK-2 and NRK49F cells. Int J Mol Sci.
20:54892019. View Article : Google Scholar
|
|
25
|
Bible KC, Kebebew E, Brierley J, Brito JP,
Cabanillas ME, Clark TJ Jr, Di Cristofano A, Foote R, Giordano T,
Kasperbauer J, et al: 2021 American thyroid association guidelines
for management of patients with anaplastic thyroid cancer. Thyroid.
31:337–386. 2021. View Article : Google Scholar
|
|
26
|
Tang J, Yang Q, Mao C, Xiao D, Liu S, Xiao
L, Zhou L, Wu G and Tao Y: The deubiquitinating enzyme UCHL3
promotes anaplastic thyroid cancer progression and metastasis
through hippo signaling pathway. Cell Death Differ. 30:1247–1259.
2023. View Article : Google Scholar
|
|
27
|
Davis JC and Waltz SE: The MET family of
receptor tyrosine kinases promotes a shift to pro-tumor metabolism.
Genes. 15:9532024. View Article : Google Scholar
|
|
28
|
Qiu Y, Cao Y, Cao W, Jia Y and Lu N: The
application of ferroptosis in diseases. Pharmacol Res.
159:1049192020. View Article : Google Scholar
|
|
29
|
McClaine RJ, Marshall AM, Wagh PK and
Waltz SE: Ron receptor tyrosine kinase activation confers
resistance to tamoxifen in breast cancer cell lines. Neoplasia.
12:650–658. 2010. View Article : Google Scholar
|
|
30
|
Logan-Collins J, Thomas RM, Yu P, Jaquish
D, Mose E, French R, Stuart W, McClaine R, Aronow B, Hoffman RM, et
al: Silencing of RON receptor signaling promotes apoptosis and
gemcitabine sensitivity in pancreatic cancers. Cancer Res.
70:1130–1140. 2010. View Article : Google Scholar
|
|
31
|
Sharma S, Zeng JY, Zhuang CM, Zhou YQ, Yao
HP, Hu X, Zhang R and Wang MH: Small-molecule inhibitor BMS-777607
induces breast cancer cell polyploidy with increased resistance to
cytotoxic chemotherapy agents. Mol Cancer Ther. 12:725–736. 2013.
View Article : Google Scholar
|
|
32
|
Kumfu S, Chattipakorn S, Fucharoen S and
Chattipakorn N: Mitochondrial calcium uniporter blocker prevents
cardiac mitochondrial dysfunction induced by iron overload in
thalassemic mice. Biometals. 25:1167–1175. 2012. View Article : Google Scholar
|
|
33
|
Dai YQ, Bai Y, Gu J and Fan BY:
Stanniocalcin1 knockdown induces ferroptosis and suppresses
glycolysis in prostate cancer via the Nrf2 pathway. Neoplasma.
69:1396–1405. 2022. View Article : Google Scholar
|
|
34
|
Zhang XY, Zhang M, Cong Q, Zhang MX, Zhang
MY, Lu YY and Xu CJ: Hexokinase 2 confers resistance to cisplatin
in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Int J Biochem Cell Biol. 95:9–16. 2018. View Article : Google Scholar
|
|
35
|
Fang J, Luo S and Lu Z: HK2: Gatekeeping
microglial activity by tuning glucose metabolism and mitochondrial
functions. Mol Cell. 83:829–831. 2023. View Article : Google Scholar
|
|
36
|
Siu YT and Jin DY: CREB-a real culprit in
oncogenesis. FEBS J. 274:3224–3232. 2007. View Article : Google Scholar
|
|
37
|
Nguyen LQ, Kopp P, Martinson F, Stanfield
K, Roth SI and Jameson JL: A dominant negative CREB (cAMP response
element-binding protein) isoform inhibits thyrocyte growth,
thyroid-specific gene expression, differentiation, and function.
Mol Endocrinol. 14:1448–1461. 2000. View Article : Google Scholar
|
|
38
|
Scheffel RS, Dora JM and Maia AL: BRAF
mutations in thyroid cancer. Curr Opin Oncol. 34:9–18. 2022.
View Article : Google Scholar
|
